Stock Financial Ratios, Dividends, Split History

FMC / FMC Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)11,882.99
Enterprise Value ($M)14,528.08
Book Value ($M)2,986.60
Book Value / Share22.20
Price / Book3.91
NCAV / Sharen/a
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 134,255,000
Common Shares Outstanding 134,330,556
Weighted Average Number Of Shares Outstanding Basic 134,255,000
Weighted Average Number Diluted Shares Outstanding Adjustment 0
Scoring Models
Piotroski F-Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.09
Return on Assets (ROA)0.09
Return on Equity (ROE)0.28
Balance Sheet (mrq) ($M)
Quick Ratio1.23
Current Ratio1.61
Income Statement (mra) ($M)
Operating Income259.80
Net Income538.40
Earnings Per Share Diluted3.99
Earnings Per Share Basic3.99
Cash Flow Statement (mra) ($M)
Cash From Operations314.50
Cash from Investing-1,349.50
Cash from Financing314.50
Identifiers and Descriptors
Central Index Key (CIK)37785
Related CUSIPS
302491903 302491953 030249130

Split History

Stock splits are used by FMC Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Domtar (UFS) Invests in Prisma to Boost Lignin Applications

2018-07-11 zacks
Domtar Corporation (UFS - Free Report) recently acquired a majority interest in Prisma Renewable Composites, LLC. This investment will help boost the process of commercializing Domtar’s lignin-based applications. Prisma Renewable Composites is a Knoxville-based spin-off of TennEra, LLC, which is primarily involved in the development of advanced materials from lignin and other natural resources. Per the investment, Domtar will employ Prisma's scientific research capabilities and unique product development strategy, alongwith its commercialization and lignin production expertise. (3-0)

Vale Rides on Stellar Steel Production Amid Inflating Costs

2018-07-11 zacks
On Jul 10, we issued an updated research report on Vale S.A. (VALE - Free Report) . The company’s performance will be backed by rise in global steel production and strong cash generation. However, its results might be marred by rising cost of sales and unfavorable exchange rates. Let’s illustrate these factors in detail. Rise in Steel Production to Boost Top Line Vale's net operating revenues in first-quarter 2018 benefited from elevated sales prices of the Base Metals segment and sturdier sales volumes of the Ferrous Minerals segment. (1-0)

CE or PPG: Which Chemical Stock is Better Pre Q2 Earnings?

2018-07-11 zacks
The chemical industry is riding an upturn in the global economy and strength across major end-use markets such as construction and automotive. Improving fundamentals in the energy space driven by an upswing in crude oil prices also augur well for the industry. Notwithstanding a few headwinds, including a spike in raw materials costs and softness in agricultural commodity prices, chemical companies are expected to continue the earnings momentum witnessed in Q1 into Q2 as the fundamental driving factors remain in place. (1-0)

Ingevity (NGVT) Stock Up 43% in a Year: What's Driving it?

2018-07-03 zacks
Shares of Ingevity Corporation (NGVT - Free Report) have rallied 43.3% in the past year against the industry’s decline of roughly 1.2%. (3-0)

Here's Why You Should Add U.S. Steel (X) to Your Portfolio

2018-07-03 zacks
United States Steel Corporation’s (X - Free Report) stock looks promising at the moment. We are positive on the company’s prospects and believe that the time is right for you to add the stock to portfolio as it is poised to carry the momentum ahead. Let’s take a look into the factors that make this steel giant a compelling choice for investors right now. What’s Working in Favor of X? Solid Rank & VGM Score: U. (3-0)

CUSIP: 302491303